Figure 2.

Western blot analysis of total Akt, pSer473-Akt, WT survivin and survivin isoforms in cytoplasmic and nuclear protein extracts of AML samples. Bone marrow aspirates from five representative AML patients at diagnosis (P1 to P5) and a control (C) from a healthy bone marrow donor. Cells were starved and maintained in a serum-free medium without cytokines for 4–5 h before protein extraction. Splicing variants of nuclear survivin are identified by different molecular weights: 2B 18 KDa, and Delta-Ex3 14 KDa and confirmed with blocking peptide experiments. Laminin-A and actin were used as controls for nuclear and cytoplasmic extracts, respectively. CytSurWT: WT cytoplasmic survivin; nSurWT: WT nuclear survivin; nSur2B: nuclear survivin 2B and nSurDEx3: nuclear survivin Delta-Ex3.